Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Therefore, a great deal of effort is being invested worldwide in developing therapeutic agents that function by fine-tuning the Wnt pathway. This article describes major milestones that have ...

结果：ADAM12 在瘢痕疙瘩组织和瘢痕疙瘩成纤维细胞中高表达。沉默 ADAM12 可抑制瘢痕疙瘩成纤维细胞的增殖、迁移、侵袭和细胞外基质（ECM）积累，促进细胞凋亡，并阻断 Wnt/β-catenin 通路。此外，证实 MeCP 2 可通过与 ADAM12 启动子结合来调节其表达。敲低 MeCP 2 可 ...

2017年7月5日，南京医科大学附属淮安第一人民医院神经外科在Oncology Research（中科院四区 IF=2）期刊上在线发表题为 "Overexpression of Protease Serine 8 Inhibits Glioma ...

Of particular significance was the finding that T3 rapidly repressed the expression of a host of key regulators of the tumor-promoting Wnt signaling pathway and the transcriptional activity of the ...

The Wnt signaling pathway is a conserved network that regulates cell proliferation, differentiation, and migration. It consists of the canonical Wnt/β-catenin pathway and non-canonical pathways ...

A recent study has uncovered the pivotal role of the transcription factor SOX9 in the development of hypospadias, a common congenital condition that affects male children.

A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of ...

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...

A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from Brown ...